



Editorial

Looking Ahead: *Clinical Hematology International* Turns One

This issue of the journal marks the first anniversary of *Clinical Hematology International* [1], the official peer-reviewed open access journal of the International Academy for Clinical Hematology (IACH; www.clinical-hematology.org). We wish the journal a happy anniversary, and we thank all of our readers, authors, reviewers, and editors for their support, dedication, and investment in the IACH activities.

In 2020, all of us involved in the hematology field find ourselves on the edge of a new decade. This is an ideal moment to look ahead and think about the future and progress. At the IACH, we are working on a variety of fronts, to offer a unique educational experience, to disseminate knowledge, and to promote good clinical practice. Therefore, we are proud to highlight the important achievements of the IACH over a short period of time. Several international meetings already took place and were highly successful in terms of both content and participation. Of note, the congress on Controversies in Multiple Myeloma (COMy) is now in its 6th edition, and has become a key moment of the international myeloma landscape. The monthly high-profile webinars are able to reach a very large audience worldwide, and progressively constitute a rich and diversified library of educational material, freely accessible anytime to all. Regional webinars and events in local languages are also being planned (e.g., in French and Spanish) to reach the highest number of colleagues and stakeholders.

During its first year of publication, our *Clinical Hematology International* journal has published high-level clinical reviews and guidelines developed by top experts who thoughtfully analyzed the available research evidence, and provided a comprehensive evaluation, to help advance the field and spread knowledge (e.g., [2–6]). The journal also published original reports, case reports, and a diverse set of material including perspective articles, commentaries, and editorials.

The IACH is committed to innovation. Looking further into the future, we envision a continuous and sustainable portfolio of activities. We want to establish strong links between the different stakeholders involved in clinical hematology worldwide, while we adapt to the field's changing expectations. This way, we are confident we will be able to make a difference for all the hematology health care professionals and, most importantly, for patients wherever they are. We are fortunate to have a dedicated team of highly skilled professionals in various capacities, who volunteer their hard work with the same excitement and enthusiasm which made us found the IACH and turn it into a leading international organization. The latter development has gone hand in hand with social responsibility, constantly advocating for patients, good clinical practice, and equal access to life saving therapies. All of this is about teamwork and a sense of fraternity to educate, raise awareness and fight blood diseases. Not all activities can be featured in a short editorial, but no matter what your interests in clinical hematology are, we would like to underline our passion to serve the community and our field. We hope you will continue to enjoy the IACH activities and to read the articles published in *Clinical Hematology International*. We always welcome your suggestions and contributions, and thank you for your trust.

© 2020 *International Academy for Clinical Hematology*. Publishing services by Atlantis Press International B.V.
This is an open access article distributed under the CC BY-NC 4.0 license (<http://creativecommons.org/licenses/by-nc/4.0/>).

REFERENCES

- [1] Mohty, M, Nagler, A, Savani, B. *Clinical Hematology International: why a new journal in hematology?* Clin Hematol Int 2019;1;1–1.
- [2] Kharfan-Dabaja, MA, Pemmaraju, N, Mohty, M. Therapeutic approaches for blastic plasmacytoid dendritic cell neoplasm: allogeneic hematopoietic cell transplantation and novel therapies. Clin Hematol Int 2019;1;2–9.
- [3] Pusic, I, Pavletic, SZ. Challenges in conducting studies in chronic graft-versus-host disease. Clin Hematol Int 2019;1;36–44.
- [4] Solomou, EE. Idiopathic aplastic anemia: an update. Clin Hematol Int 2019;1;52–7.
- [5] Jacoby, E. Relapse and resistance to CAR-T cells and blinatumomab in hematologic malignancies. Clin Hematol Int 2019;1;79–84.
- [6] Bussel, J, Miltiadous, O. Immune thrombocytopenia: are we stuck in the mud or is there light at the end of the tunnel? Clin Hematol Int 2019;1;173–9.

Mohamad Mohty^{1,*}, Arnon Nagler², Bipin Savani³

¹Sorbonne University, service d'Hématologie Clinique et thérapie cellulaire, Saint Antoine Hospital, and INSERM UMRs 938, Paris, France

²Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel

³Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

*Corresponding author. Email: mohamad.mohty@inserm.fr